breast cancer – Medxy AI

Patritumab Deruxtecan (HER3-DXd) Shows Promising Activity in Breast Cancer Patients with Active Brain Metastases: Insights from the TUXEDO-3 Phase 2 Trial

By MedXY 10/31/2025

The TUXEDO-3 trial demonstrates that patritumab deruxtecan, a HER3-targeted antibody-drug conjugate, offers clinical benefit and a manageable safety profile in metastatic breast cancer patients with active brain metastases.

OB/GYN & Women's Health Oncology

Innovative Oral SERD Plus Everolimus Therapy Shows Superior Efficacy in Advanced ER+ HER2- Breast Cancer

By MedXY 10/24/2025

Roche announces positive phase 3 results of giredestrant plus everolimus, significantly reducing disease progression risk in ER+ HER2- advanced breast cancer patients post CDK4/6 inhibitor exposure, with favorable safety and promising survival trends.

Cardiology news Oncology

Predicting Heart Failure Risk in Women Treated for Breast Cancer: A New Clinical Tool

By MedXY 10/24/2025

A novel risk prediction model for 10-year heart failure or cardiomyopathy offers tailored cardiac management strategies for women undergoing breast cancer therapy.

news Oncology

Enhancing Fertility Preservation and Ovarian Function in Young Women with Breast Cancer: Insights from International Prospective Studies

By MedXY 10/22/2025

This article reviews a joint analysis of the Joven & Fuerte and PREFER studies, highlighting disparities in fertility preservation strategies among Mexican and Italian young women with breast cancer, and discusses implications for clinical practice.

Hematology-Oncology OB/GYN & Women's Health Specialties

Ki-67 Dynamics During Neoadjuvant Chemotherapy: A Key to Better Breast Cancer Prognosis

By MedXY 10/18/2025

This study highlights the prognostic significance of tumor Ki-67 changes during neoadjuvant treatment, offering potential for improved risk stratification and personalized therapy in breast cancer patients.

OB/GYN & Women's Health Oncology Specialties

Assessing the Nationwide Prevalence and Outcomes of Breast Cancer Patients Eligible for Adjuvant CDK4/6 Inhibitors

By MedXY 10/18/2025

This study offers insights into the prevalence, characteristics, and long-term survival of breast cancer patients eligible for adjuvant CDK4/6 inhibitors, highlighting real-world outcomes compared to clinical trial populations.

news Oncology

Unlocking Prognostic and Therapeutic Insights in Breast Cancer Through Whole-Genome Sequencing Linked With Mortality Data

By MedXY 10/15/2025

This retrospective UK study reveals that integrating whole-genome sequencing with clinical and mortality data enhances prognostication and identifies therapeutic targets in breast cancer, particularly in ER-positive, HER2-negative subtypes.

news Oncology

Quantifying Breast Cancer Risk: The Impact of Pathogenic Variants and Family History in US Women

By MedXY 10/10/2025

This study evaluates cumulative breast cancer risks among US women based on pathogenic variant status and family history, revealing significant risk stratification that informs personalized screening and prevention.

Oncology Public Health

Rising Incidence of Breast Cancer Among Young Women: Trends and Implications from 1990 to 2023

By MedXY 10/09/2025

Early-onset breast cancer incidence in France has steadily increased over the past three decades, mirroring trends in other Western countries. Shifts in hormonal and lifestyle factors may contribute, highlighting the need for adapted prevention and screening strategies.

news OB/GYN & Women's Health Oncology Radiology Specialties

Impact of Immediate Past Mammography Participation on Outcomes of Screen-Detected Breast Cancer

By MedXY 10/04/2025

This cohort study reveals that women with screen-detected breast cancer who missed the immediate prior mammography screening have larger tumors, more advanced disease, and worse breast cancer-specific survival, suggesting delayed detection and poorer prognosis.

Clinical Updates Oncology Specialties

Deciphering the Role of Intratumoral Microbiota in Breast Cancer: Pathogenesis to Precision Therapeutics

By MedXY 09/30/2025

Intratumoral microbiota significantly influence breast cancer development, progression, and therapeutic response. Their diverse composition across subtypes presents diagnostic and prognostic opportunities. Emerging strategies target these microbes to improve treatment efficacy and overcome resistance.

Clinical Updates Oncology

Novel Heparanase Inhibitor LMW-DSS Shows Promise in Preventing Breast Cancer Metastasis by Targeting Migration and Angiogenesis

By MedXY 09/30/2025

Low-molecular-weight dextran sulfate sodium (LMW-DSS), a new heparanase inhibitor, effectively prevents breast cancer metastasis in mice by inhibiting cancer cell migration and angiogenesis, offering a promising therapeutic approach with minimal bleeding risk.

OB/GYN & Women's Health Oncology Specialties

Evolving Trends and Economic Implications of Breast Cancer Screening in Older US Women: Navigating Value and Cost

By MedXY 09/28/2025

Breast cancer screening among older US women shows stable use but rising costs driven by low-value technologies; optimizing screening strategies could enhance value and reduce expenditure.

Family Medicine & Nutrition Oncology Specialties

Vitamin B12 Supplementation Halves Risk of Chemotherapy-Induced Hand-Foot Syndrome in Early Breast Cancer Patients

By MedXY 09/25/2025

A phase 3 trial finds high-dose oral vitamin B12 significantly reduces moderate-to-severe hand-foot syndrome in women receiving capecitabine chemotherapy, without increasing toxicity, offering a safe and convenient preventive option.

Clinical Updates news Oncology Specialties

Is Lower-Dose Ribociclib Equally Effective in Hormone Receptor-Positive/ERBB2-Negative Breast Cancer?

By MedXY 09/25/2025

Lower-dose ribociclib (400 mg) does not demonstrate noninferior response rates compared to the standard 600 mg dose in advanced HR+/ERBB2- breast cancer but shows reduced toxicity and comparable progression-free survival, supporting 600 mg as the starting dose with dose reductions for adverse events.

Clinical Updates news OB/GYN & Women's Health Specialties

Top Ten Research Priorities in Menopause: A Comprehensive Evidence-Based Review

By MedXY 09/07/2025

This review synthesizes the Menopause Priority Setting Partnership findings, highlighting the top ten evidence-based research priorities addressing non-hormonal treatments, lifestyle interventions, cognitive and sleep changes, hormone therapy duration, global experiences, breast cancer management, dementia risk, and personalized hormone therapy safety.

Cardiology news Oncology Specialties

Sacubitril-Valsartan for Cardiac Protection During Breast Cancer Therapy: Insights from the PRADA II Trial

By MedXY 09/06/2025

The PRADA II trial evaluated sacubitril-valsartan for preventing cardiac dysfunction during anthracycline-based breast cancer therapy. While it did not significantly preserve left ventricular ejection fraction, improvements in myocardial strain and cardiac biomarkers suggest a potential role in cardioprotection.

news Oncology Specialties

Targeting Dormant Tumor Cells: A Promising Strategy to Prevent Breast Cancer Recurrence

By MedXY 09/04/2025

A phase 2 randomized trial demonstrates that targeting dormant disseminated tumor cells with hydroxychloroquine and everolimus is safe, feasible, and reduces minimal residual disease, potentially improving recurrence-free survival in breast cancer survivors.

Family Medicine & Nutrition Medical News news Oncology Specialties

Understanding Breast Cancer Risk: Habits and Genetic Factors That Quietly Increase Danger

By MedXY 08/23/2025

Breast cancer is the most common cancer among women, with 90% of patients belonging to high-risk groups. This article explores five major risk factors, early detection strategies, and lifestyle changes crucial for prevention.

OB/GYN & Women's Health Oncology Specialties

Elinzanetant for Vasomotor Symptoms in Endocrine Therapy for Breast Cancer: A Phase 3 Evidence Synthesis

By MedXY 08/21/2025

This review analyzes the pivotal phase 3 trial demonstrating elinzanetant’s efficacy and safety in reducing vasomotor symptoms among women undergoing endocrine therapy for HR-positive breast cancer or prevention.